a public good project by the
Synthesis
Company
of California

© 2026

Lynne D. Berry | doi.page

0 works0 citations0 h-index

Lynne D. Berry

Berry & Associates (United States)(US)Vanderbilt University Medical Center(US)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, RNA modifications and cancer, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment

Most-Cited Works

→ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs(2014)1,725 cited
→ The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution(2020)574 cited
→ Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience(2015)425 cited
→ Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps(2021)324 cited
→ Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience(2019)236 cited
→ Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma(2013)221 cited

→ The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)(2017)

215 cited

→ Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).(2011)214 cited

→ HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium(2017)195 cited

→ MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium(2019)173 cited